| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5480656 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5643607 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5575987 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5716640 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5631020 | ABBVIE ENDOCRINE INC | Method for producing microcapsule |
May, 2014
(9 years ago) | |
| US5631021 | ABBVIE ENDOCRINE INC | Method for producing microcapsule |
May, 2014
(9 years ago) | |
| US6036976 | ABBVIE ENDOCRINE INC | Sustained release microspheres and preparation thereof |
Dec, 2016
(7 years ago) | |
| US7429559 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jan, 2019
(5 years ago) | |
| US8815801 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jun, 2022
(1 year, 10 months ago) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(6 years from now) | |
Lupron Depot is owned by Abbvie Endocrine Inc.
Lupron Depot contains Leuprolide Acetate.
Lupron Depot has a total of 10 drug patents out of which 9 drug patents have expired.
Expired drug patents of Lupron Depot are:
- US5480656
- US5643607
- US5575987
- US5716640
- US5631020
- US5631021
- US6036976
- US7429559
- US8815801
Lupron Depot was authorised for market use on 22 December, 1995.
Lupron Depot is available in injectable;injection dosage forms.
Lupron Depot can be used as palliative treatment of prostate cancer.
The generics of Lupron Depot are possible to be released after 05 February, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Jun 17, 2014 |
| New Dosing Schedule(D-132) | Jun 17, 2014 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 22 December, 1995
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
LUPRON DEPOT family patents
